27 related articles for article (PubMed ID: 30872381)
1. Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
Ramkumar K; Tanimoto A; Della Corte CM; Stewart CA; Wang Q; Shen L; Cardnell RJ; Wang J; Polanska UM; Andersen C; Saeh J; Pease JE; Travers J; Fabbri G; Gay CM; Urosevic J; Byers LA
Clin Cancer Res; 2023 Aug; 29(16):3237-3249. PubMed ID: 37289191
[TBL] [Abstract][Full Text] [Related]
2. The PET-Tracer
Griessinger CM; Olafsen T; Mascioni A; Jiang ZK; Zamilpa C; Jia F; Torgov M; Romero JM; Marchioni F; Satpayev D; Lee C; Zhang G; Nayak TK; Pincha M; Amann M; Mohan PLB; Richard M; Nicolini VG; Sam J; Claus C; Ferrara C; Brünker P; Bacac M; Umana P; Rüttinger D; Wilson IA; Gudas J; Klein C; Tessier JJL
Cancer Res; 2020 Jul; 80(13):2903-2913. PubMed ID: 32409308
[TBL] [Abstract][Full Text] [Related]
3. Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance.
Raj SR; Guzman JC; Harvey P; Richer L; Schondorf R; Seifer C; Thibodeau-Jarry N; Sheldon RS
Can J Cardiol; 2020 Mar; 36(3):357-372. PubMed ID: 32145864
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells.
Shah ET; Molloy C; Gough M; Kryza T; Samuel SG; Tucker A; Bhatia M; Ferguson G; Heyman R; Vora S; Monkman J; Bolderson E; Kulasinghe A; He Y; Gabrielli B; Hooper JD; Richard DJ; O'Byrne KJ; Adams MN
Br J Cancer; 2024 Apr; 130(7):1196-1205. PubMed ID: 38287178
[TBL] [Abstract][Full Text] [Related]
5. Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies.
Li J; Wang Q; Han Y; Jiang L; Lu S; Wang B; Qian W; Zhu M; Huang H; Qian P
J Hematol Oncol; 2023 Jun; 16(1):65. PubMed ID: 37353849
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours.
Johnson ML; Wang JS; Falchook G; Greenlees C; Jones S; Strickland D; Fabbri G; Kennedy C; Elizabeth Pease J; Sainsbury L; MacDonald A; Schalkwijk S; Szekeres P; Cosaert J; Burris H
Br J Cancer; 2023 May; 128(10):1906-1915. PubMed ID: 36871042
[TBL] [Abstract][Full Text] [Related]
7. Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies.
Markouli M; Strepkos D; Piperi C
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362442
[TBL] [Abstract][Full Text] [Related]
8. Clinical considerations for the design of PROTACs in cancer.
Nieto-Jiménez C; Morafraile EC; Alonso-Moreno C; Ocaña A
Mol Cancer; 2022 Mar; 21(1):67. PubMed ID: 35249548
[TBL] [Abstract][Full Text] [Related]
9. Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles.
Juan A; Del Mar Noblejas-López M; Arenas-Moreira M; Alonso-Moreno C; Ocaña A
Front Cell Dev Biol; 2021; 9():805336. PubMed ID: 35186955
[TBL] [Abstract][Full Text] [Related]
10. Histone Modifications and Their Targeting in Lymphoid Malignancies.
Fernández-Serrano M; Winkler R; Santos JC; Le Pannérer MM; Buschbeck M; Roué G
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008680
[TBL] [Abstract][Full Text] [Related]
11. Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.
Borah NA; Reddy MM
Molecules; 2021 Apr; 26(7):. PubMed ID: 33915740
[TBL] [Abstract][Full Text] [Related]
12. Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells.
Wu ZX; Yang Y; Wang JQ; Zhou WM; Chen J; Fu YG; Patel K; Chen ZS; Zhang JY
Front Pharmacol; 2020; 11():615824. PubMed ID: 33519482
[TBL] [Abstract][Full Text] [Related]
13. Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.
Goto H; Yoshino Y; Ito M; Nagai J; Kumamoto T; Inukai T; Sakurai Y; Miyagawa N; Keino D; Yokosuka T; Iwasaki F; Hamanoue S; Shiomi M; Goto S
Cancer Chemother Pharmacol; 2020 Apr; 85(4):773-783. PubMed ID: 32144432
[TBL] [Abstract][Full Text] [Related]
14. Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
Floc'h N; Ashton S; Ferguson D; Taylor P; Carnevalli LS; Hughes AM; Harris E; Hattersley M; Wen S; Curtis NJ; Pilling JE; Young LA; Maratea K; Pease EJ; Barry ST
Mol Cancer Ther; 2019 May; 18(5):909-919. PubMed ID: 30872381
[TBL] [Abstract][Full Text] [Related]
15. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST
Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.
Ashton S; Song YH; Nolan J; Cadogan E; Murray J; Odedra R; Foster J; Hall PA; Low S; Taylor P; Ellston R; Polanska UM; Wilson J; Howes C; Smith A; Goodwin RJ; Swales JG; Strittmatter N; Takáts Z; Nilsson A; Andren P; Trueman D; Walker M; Reimer CL; Troiano G; Parsons D; De Witt D; Ashford M; Hrkach J; Zale S; Jewsbury PJ; Barry ST
Sci Transl Med; 2016 Feb; 8(325):325ra17. PubMed ID: 26865565
[TBL] [Abstract][Full Text] [Related]
17. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
19. Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.
Ghanizadeh-Vesali S; Zekri A; Zaker F; Zaghal A; Yousefi M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Ann Hematol; 2016 Jun; 95(7):1031-42. PubMed ID: 27091351
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
